{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-008948","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2024-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.634707+00:00","generated_at":"2026-05-28T23:44:38.136574+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tivic Health reports >65% DTC gross margin, advances VNS program with Feinstein Institute","bullets":["ClearUP 2.0 launched; McKesson & Cardinal Health partnerships accelerating; customer reviews 4.4 stars; defect returns down.","D2C gross margin over 65% (vs <28% in 2023); net operating loss reduced more than 30%.","VNS pilot study with Feinstein Institute showed best-in-industry results; second study fully enrolled, data expected next year.","Targeting $30B+ annual market opportunity in non-invasive VNS; 16 issued patents, 10 pending internationally.","Plans disease-specific clinical trials in 2025, working to regain Nasdaq compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-008948","json":"https://secwatch.observer/filing/0001683168-24-008948.json","markdown":"https://secwatch.observer/filing/0001683168-24-008948.md","text":"https://secwatch.observer/filing/0001683168-24-008948.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000168316824008948/0001683168-24-008948-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000168316824008948/tivic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:44:38.136574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}